Note: Descriptions are shown in the official language in which they were submitted.
~"~ t~
-- 1 --
59304000.sGo
~yclic IminQ Derivatives
The present invention relates to new cyclic imino
derivatives, processes for their preparation and
pharmaceutical compositions containing then~.
It has been found that certain novel cyclic imino
derivatives possess particularly valuable
pharmacological properties, in particular, aggregation-
inhibiting effects.
Thus, viewed from one aspect the invention provides
compounds of formula I:
B X2 X1 A - Y E (I)
(wherein
with the proviso that
(i) B denotes an R1-C0-0-(R2CR3)-0-C0-NH-C(=NH)- or
(R40)PO(ORs)-NH-C(=NH)- group or
E denotes a l,3-dihydro-3-oxo-l-isobenzofuranyloxy-
carbonyl, R6-C0-0-CHR7-0-C0- or R80-C0- group, or
(ii) B denotes an P~-C0-0-(R2CR3)-0-C0-NH-C(=NH~- or
(R40)PO(ORs)-NH-C(=NH)- group and
E denotes a l,3-dihydro-3-oxo-l-isobenzofuranyloxy-
carbonyl, Rb-C0-0-CHR7-0-C0- or R80-C0- group
in which one of the two imino groups contained in the
group B may additionally be substituted by a methyl
group, wherein
R1 denotes a C11s-alkyl group, a C37-cycloalkyl group, a
phenyl group or a phenyl(C13-alkyl~ group,
R2 and R3, which may be identical or different, denote
~ .J~J~
2 --
hydrogen atoms or Cl6-alkyl groups or one of the groups
R2 and R3 may additionally denote a C37-cycloalkyl group
or a phenyl group,
R4 and Rs~ which may be identical or differ~nt, denote
hydrogen atoms, Cl4-alkyl groups, benzyl or ph~nyl
groups,
R6 denotes a C17-alkyl group, a C27-alkenyl group, a C3 7-
cycloalkyl group, a C16-alkoxy group, a C47-cycloalkoxy
group, a phenyl or phenoxy group, a phenyl(C13-alkyl) or
phenyl(C13-alkoxy) group, or a 2-phenylvinyl or 3-
phenylallyloxy group,
R7 denotes a hydrogen atom, a C16-alkyl group, a C37-
cycloalkyl group or a phenyl group, and
R8 denotes a C48-cycloalkyl group or a C38-cycloalkyl-
(C13-alkyl) group, wherein the cycloalkyl moieties may
additionally be substituted by 1 to 4 C~4-alkyl groups,
by one or two C14-alkoxy groups or by one or two di(C14-
alkyl)amino groups which substituents may be identical
or different, by a fluorine, chlorine or bromine atom,
or by a phenyl, trifluoromethyl or C36-cycloalkyl group,
and moreover, in the above-mentioned cycloalkyl moieties
which contain 4 to 8 carbon atoms, a methylene group may
be replaced by an oxygen or sulphur atom, by a cl4-
alkylimino group or by a sulphinyl, sulphonyl,
acetylimino or methanesulphonylimino group,
a C58-cycloalkenyl or C5~-cycloalkenyl(C13-alkyl) group,
wherein the cycloalkenyl moieties may additionally be
substituted by 1 to 4 C14-alkyl groups, with the proviso
that the above-mentioned cycloalkenyl moieties are not
linked to the oxygen atom of the adjacent -O-CO- group
via a carbon atom from which a double bond starts,
- 3 -
a C610-bicycloalkyl or C~O-bicycloalkyl(C13-alkyl) group,
wherein the bicycloalkyl moieties may additionally be
substituted by 1 to 3 methyl groups,
a C7 10-tricycloalkyl or C710-tricycloalkyl(C13-alkyl)
group, wherein the tricycloalkyl moieties may
additionally be substituted by 1 to 3 methyl groups,
a C7~0-bicycloalkenyl or C710-bicycloalkenyl(C13-alkyl)
group, wherein the bicycloalkenyl moieties may
additionally be substituted by 1 to 3 methyl groups,
with the proviso that the above-mentioned bicycloalkenyl ~.
moieties are not linked to the oxygen atom of the
adjacent -O-CO- group via a carbon atom from which a
double bond starts,
a C912-benzocycloalkyl group wherein the cycloalkyl .
moiety may be substituted by 1 or 2 methyl groups and
the aromatic moiety may additionally be mono- or
disubstituted by fluorine, chlorine or bromine atoms or
by methyl, ethyl, methoxy, ethoxy, trifluoromethyl,
cyano or methanesulphonyl groups and the substituents
may be identical or different,
a C36-alkenyl or C36-alkynyl group, optionally
substituted by a phenyl group, with the proviso that the
alkenyl or alkynyl groups are not linked to the oxygen
atom of the adjacent -O-CO- group via a carbon atom from
which a double or triple bond starts,
wherein any phenyl group mentioned above may be mono- or
disubstituted by fluorine, chlorine or bromine atoms or
by methyl, ethyl, methoxy, ethoxy, trifluoromethyl,
cyano or methanesulphonyl groups and the substituents
may be identical or different;
A denotes a pyrrolidine or 2-pyrrolidinone ring
optionally substituted by the groups R9 and R~o~ wherein
R9 denotes a phenyl group optionally substituted by
a fluorine, chlorine or bromine atom or by a
methyl, methoxy, carboxy, methoxycarbonyl or
dimethylaminocarbonyl group,
a C14-alkyl group optionally substituted by a
cyclohexyl group or by two phenyl groups, or a
straight-chained C14-alkyl gro~p substituted by a
phenyl group itself optionally mono- or
disubstituted by Cl4-alkyl, C16-alkoxy, phenyl,
benzyl, methylsulphenyl, methylsulphonyl or
trifluoromethyl groups or by fluorine, chlorine or
bromine atoms, wherein the substituents may be
identical or different,
`;'I;~!
a C24-alkyl group substituted in the 2-, 3- or 4-
positisn by a hydroxy, methoxy or phenoxy group,
a methyl group substituted by a carboxy,
methoxycarbonyl, aminocarbonyl, methylamino-
carbonyl, ethylaminocarbonyl,
dimethylaminocarbonyl, diethylaminocarbonyl,
benzylaminocarbonyl, pyrrolidinocarbonyl,
piperidinocarbonyl or morpholinocarbonyl group,
or, if A denotes a pyrrolidine ring, R9 may also
denote a carbonyl group substituted by a methyl,
phenyl, methylamino, ethylamino, dimethylamino,
diethylamino or methoxymethyl group or R9 in the l-,
3- or 4-position may denote a sulfonyl group
substituted by a methyl, phenyl, methoxyphenyl or
dimethylamino group or R9 in the l-position may
denote an aminomethylcarbonyl group,
or, if A denotes a 2-pyrrolidinone ring, R9 in the
~ ~ ~ t~
3- or 4-position may also denote a sulfonyl group
substituted by a methyl, phenyl, methoxyphenyl or
dimethylamino group or R9 in the 3-, 4- or 5-
position may denote a carbonyl group substituted by
a methyl, phenyl, methylamino, ethylamino,
dimethylamino, diethylamino or methoxymethyl group,
and
R10 denotes a C14-alkyl group;
B denotes an HNR11-C(=NH)- group wherein R11 denotes a
hydrogen atom, a C~4-alkyl group, a ~C14-alkoxy)carbonyl
group, a phenoxycarbonyl, benzyloxycarbonyl group, or B
denotes an R1-CO-O-(R2CR3)-O-CO-NH-C(=NH)- or
(R40)PO(ORs)-NH-C(=NH)- group wherein R1, R2, R3, R4 and Rs
are as hereinbefore defined and one of the two imino
groups contained in the group B may additionally be
substituted by a methyl group;
Y denotes a straight-chained or branched C14-alkylene
group;
E denotes a carboxy, phosphono, O-methyl-phosphono or 0-
ethyl-phosphono group, a di(C14-alkyl)aminocarbonyl-
methoxycarbonyl group, a (C16alkoxy)carbonyl group
wherein a methoxy moiety may be substituted by a phenyl
or pyridyl group, an ethoxy moiety by a phenyl or
dimethoxyphenyl group or in the 2-position by a
morpholino or 2-oxo-1-pyrrolidinyl group and an n-
propoxy moiety may be substituted by a phenyl group, or
E denotes a l,3-dihydro-3-oxo-1-isobenzofuranyloxy-
carbonyl group, an R6-CO-O-CHR7-O-CO- group or an R80-CO-
group, wherein R6, R7 and R8 are as hereinbefore defined
and the shortest distance of the group E from the first
nitrogen atom of group B is at least 10 bonds;
X1 denotes a bond, a methylene group which, provided it
"-,~,J~J~ 'J .~'
-- 6
is not bound to the ring nitrogen atom of group ~, is
bound to ~he adjacent X2 group via an oxygen atom, a
sulphonyl, NRlz-, -CO-NH , -NH-CO- or -SO2-NH- group,
wherein R12 denotes a hydrogen atom or a methyl, ethyl,
acetyl or methanesulphonyl group and the sulphonyl group
of the above-mentioned -SO2-NH- group is linked to the
group X2, or X1 denotes an ethylene group which is bound
to the adjacent group X2 via an oxygen atom or via a
-CONH- group, ln which the carbonyl group of the -CONH-
group is linked to the group X2; and
X2 denotes a biphenylylene group optionally substituted
by a fluorine, chlorine, bromine or iodine atom, by a
methyl, methoxy, ethoxy, trifluoromethyl,
methylsulphenyl, methylsulphinyl, methylsulphonyl,
nitro, acetylamino or methanesulphonylamino group or by Y
another methyl group, or X2 denotes a phenylene(C46-
cycloalkylene) group, a phenylenesulphenylphenylene,
phenylenesulphinylphenylene, phenylenesulphonyl-
phenylene, dihydrophenanthrenylene, indanylene or
naphthylene group or a fluorenylene group in which the
methylene group may be replaced by a hydroxymethylene or
carbonyl group)
and the stereoisomers and tautomers, the mixtures and
the salts thereof.
Preferred compounds according to the invention include
those of formula I wherein
with the proviso that
(i) B denotes an R1-CO-O-(R2CR3)-O-CO-NH-C(=NH)- or
(R40)PO(ORs)-NH-C(=NH)- group or
E denotes a 1,3-dihydro-3-oxo-1-isobenzofuranyloxy-
carbonyl, R6-CO-O-CHR7-O-CO- or R~O-CO- group, or
(iij B denotes an R1-CO-O-(R2CR3)-O-CO-NH-C(=NH)- or
s~ ''g
-- 7 --
(R40~PO(ORs)-NH-C(=NH)- group and
E denotes a 1,3-dihydro-3-oxo-1-isobenzofuranyloxy-
carbonyl, R6-CO-O-CHR7-O-CO- or R80-CO- group,
wherein
Rl denotes a C14-alkyl group or a phenyl(Cl3 alkyl)
group,
R2 denotes a hydrogen atom or a methyl or ethyl
group,
R3 denotes a hydrogen atom, :i
R4 and R5, which may be identical or different, :.
denote hydrogen atoms or Cl4-alkyl groups, .i'
R6 denotes a cl7 alkyl, Cs7-cycloalkyl, Cl4-alkoxy,
Cs7-cycloalkoxy, phenyl or phenoxy group or a
phenyl(C13-alkyl) or phenyl(C13-alkoxy) group,
R7 denotes a hydrogen atom, a C13-alkyl group, a
C~7-cycloalkyl group or a phenyl group, and
R8 denotes a C48-cycloalkyl group or a C38-
cycloalkyl(C13-alkyl) group, wherein the cycloalkyl
moieties may additionally be substituted by a C1 4-
alkyl group or by a C14-alkyl group and l to 3
methyl groups or ky a C14-alkoxy or di(C14-
alkyl)amino group, and moreover a methylene group
in the above-mentioned cycloalkyl moieties which
contain 4 to 8 carbon atoms may be replaced by an
oxygen or sulphur atom, by a ~C14-alkyl)imino
group, or by a sulphinyl or sulphonyl group, with
the proviso that there are at least two carbon
atoms between the ring heteroatom and the next
heteroatom,
a CsB-cycloalkenyl or Cs8-cycloalkenyl(C13-alkyl)
group, wherein the cycloalkenyl moieties may
additionally be substituted by a C14-alkyl group or
by a C14-alkyl group and 1 to 3 methyl groups, with
the proviso that the above-mentioned cycloalkenyl
moieties are not linked to the oxygen atom of the
adjacent -O-CO- group via a carbon atom from which
a double bond starts,
a C610-bicycloalkyl or C610-bicycloalkyl(C13-alkyl)
group, wherein the bicycloalkyl moieties may
additionally be substituted by 1 to 3 methyl
groups,
.
a C710-bicycloalkenyl or C710-bicycloalkenyl(C1 3- ''!'
alkyl) group, wherein the bicycloalkenyl moieties
may additionally be substituted by 1 to 3 methyl ~s
groups, with the proviso that the above-mentioned
bicycloalkenyl moieties are not linked to the
oxygen atom of the adjacent -O-CO- group via a
carbon atom from which a double bond starts,
a C9 12-benzocycloalkyl group wherein the cycloalkyl
moiety may be substituted by 1 or 2 methyl groups
and the aromatic moiety may additionally be mono-
or disubstituted by fluorine, chlorine or bromine
atoms or by methyl, ethyl, methoxy, ethoxy,
trifluoromethyl, cyano or methanesulphonyl groups
and the substituents may be identical or different,
a C3 6-alkenyl or C3 6-alkynyl group optionally
substituted by a phenyl group, with the proviso
that the above-mentioned alkenyl or alkynyl groups
are not linked to the oxygen atom of the adjacent
-o-Co- group via a carbon atom from which a double
or triple bond starts;
$ ~
A denotes a pyrrolidine or 2-pyrrolidinone ring
optionally substituted by the groups R9 and Rlo, wherein
R9 denotes a phenyl group,
an optionally cyclohexyl-substituted C1~4-alkyl
group or a straight-chained Cl4-alkyl group
terminally substituted by a phenyl group optionally
mono- or disubstituted by C12-alkyl, C12-alkoxy,
methylsulphonyl or trifluoromethyl groups or by
fluorine or chlorine atoms, wherein the
substituents may be identical or different, ~!
'';
a C24-alkyl group terminally substituted by a
hydroxy, methoxy or phenoxy group,
a methyl group substituted by a dimethyl-
aminocarbonyl, pyrrolidinocarbonyl or i;
morpholinocarbonyl group,
ox, if A denotes a pyrrolidine ring, R9 may also
denote a carbonyl group substituted by a methyl,
phenyl, dimethylamino or methoxymethyl group, or R9
in the 1-, 3- or 4-position may denote a sulfonyl
group substituted by a methyl, phenyl,
methoxyphenyl or dimethylamino group,
or, if A denotes a 2-pyrrolidinone ring, R9 in the
3- or 4-position may also denote a sulphonyl group
substituted by a methyl, phenyl, methoxyphenyl or
dimethylamino group, or R9 in the 3-, 4- or 5-
position may denote a carbonyl group substituted by
a methyl, phenyl, dimethylamino or methoxymethyl
group and
R1o denotes a C12-alkyl group;
~ v 13 ~ i~ v ~
-- 10 ~
B denotes an ~NR11-C(~NH)- group wherein ~11 is a hydrogen
atom, a C12-alkyl group, a (C12-alkoxy)carbonyl group or
a benzyloxycarbonyl group, or B denotes an
R1-C0-0-(R2CR3)-0-C0-NH-C(=NH)- or (R40)P0(ORs)-NH-C(=NH)--
g up wherein R1~ R2~ ~3~ R4 and Rs are as hereinbeforedefined;
Y denotes a methylene group;
E denotes a carboxy group, a (C16-alkoxy)carbonyl group
in which a methoxy moiety may be substituted by a phenyl
group, an ethoxy moiety by a phenyl or dimethoxyphenyl ?,i
group and an n-propoxy moiety by a phenyl group, or E
denotes a l,3-dihydro-3-oxo-l-isobenzofuranyloxycarbonyl
group, an R6-C0-0-CHR7-0-C0- group or an ~80-C0- group,
wherein R6, R7 and R8 are as hereinbefore defined and the
shortest distance of the group E from the first nitrogen
atom of group B is at least lO bonds; .~.,
j
X1 denotes a bond, a methylene group which, if it is not
bound to the ring nitrogen atom of group A, is bound to
the adjacent X2 group via an oxygen atom or a sulphonyl,
-NR12-, -C0-NH- or -S02NH- group, wherein R12 denotes a
hydrogen atom or a methyl or acetyl group, or X1 denotes
an ethylene group which is bound to the adjacent X2 group
via a -C0-NH- group, whilst the carbonyl and sulphonyl
group of the above-mentioned -C0-NH- and -S02-NH- groups
are linked to the group X2; and
X2 denotes a biphenylylene group optionally substituted
by a fluorine or chlorine atom or by a methyl, methoxy,
ethoxy, trifluoromethyl, methylsulphonyl, acetylamino or
methanesulphonylamino group or by another methyl group,
or X2 denotes a phenylene(C46-cycloalkylene) group, a
dihydrophenanthrenylene group or a fluorenylene group in
which the methylene group may be replaced by a carbonyl
group;
~'J t~
-- 11 --
and the stereoisomers and tautomers, the mixtures and
the salts thereof.
Particularly preferred compounds according to the
invention include those of formula I wherein,
with the proviso that
(i) B denotes an R1-CO-O-(R2CR3)-O-CO-NH-C(=NH)- or
(R40)PO(OR5)-NH-C(=NH)- group or
E denotes a l,3-dihydro-3-oxo-l-isobenzofuranyloxy-
carbonyl, R6-CO-O-CHR7-O-CO- or R80-CO- group, or
(ii) B denotes an R1-CO-O-(RzCR3)-O-CO-NH-C(=NH)- or.
(R40)PO(ORs)-NH-C(=NH)- group and
E denotes a l,3-dihydro-3-oxo-l-isobenzofuranyloxy-
carbonyl, R6-CO-O-CHR7-O-CO- or R80-CO- group,
wherein
R1 denotes a C14-alkyl group,
R2 is a hydrogen atom or a methyl group,
R3 is a hydrogen atom,
R4 and R5, which may be identical or different,
denote hydrogen atoms or methyl or ethyl groups,
R6 denotes a C14-alkyl group, a C57-cycloalkyl
group, a C14-alkoxy group, a Cs7-cycloalkoxy group
or a phenyl group,
R7 denotes a hydrogen atom or a C13-alkyl group and
R8 denotes a C58-cycloalkyl group or a C38-
cycloalkyl(C13-alkyl) group, wherein the cycloalkyl
moieties may additionally be substituted by a C14-
alkyl group or by a C14-alkyl group and l to 3
- 12 -
methyl groups, by a C14~alkoxy or di(C14-alkyl)amino
group and moreover in the cycloalkyl moieties
mentioned above which contain 4 to 8 carbon atoms,
a methylene group may be replaced by an oxygen atom
or by a methylimino or ethylimino group, with the
proviso that there are at least 2 carbon atoms
between the ring heteroatom and the next
heteroatom,
a Cs8-cycloalkenyl or C58-cycloalkenyl(C13-alkyl)
group, wherein the cycloalkenyl moieties may
additionally be substituted by one or two methyl h
groups, with the proviso that the above-mentioned ~!
cycloalkenyl moieties are not linked to the oxygen ~,
atom of the adjacent -O-CO~ group via a carbon atom
from which a double bond starts,
a C68 hicycloalkyl or C6s-bicycloalkyl(Cl3-alkylJ ~;'
group, in which the bicycloalkyl moieties may . p
additionally be substituted by 1 to 3 methyl
groups,
a C78-bicycloalkenyl or C78-bicycloalkenyl(C1 3-
alkyl) group, in which the bicycloalkenyl moieties
may additionally be substituted by l to 3 methyl
groups, with the proviso that the above-mentioned
bicycloalkenyl moieties are not linked to the
oxygen atom of the adjacent -O-CO- group via a
carbon atom from which a double bond starts,
a benzo(C3s-cycloalkyl) group, wherein the aromatic
moiety may be substituted by a fluorine, chlorine
or bromine atom, or by a methyl, ethyl, methoxy,
ethoxy, trifluoromethyl, cyano or methanesulphonyl
group,
an optionally phenyl-substituted C36-alkenyl or C36-
J' rj U ~1 t~
- 13 -
alkynyl group, with the pro~iso that the above-
mentioned al~enyl or alkynyl groups are not linked
to the oxygen atom of the adjacent -0-C0- group via
a carbon atom from which a double or triple bond
starts;
A denotes a pyrrolidine or 2-pyrrolidinone ring
optionally methyl-substituted in the carbon skeleton,
wherein the pyrrolidine ring is substituted in the 1-
position by an acetyl, benzoyl, dimethylaminocarbonyl,
methoxyacetyl, methanesulphonyl, phenylsulphonyl, 4-
methoxyphenylsulphonyl or dimethylaminosulphonyl group
and the pyrrolidinone ring is substituted in the 1-
position by a phenyl group, by a straight-chained Cî4~
alkyl group terminally substituted by a phenyl group .
(which may be substituted by a methyl, methoxy, '5
methanesulphonyl or trifluoromethyl group or by two s-
methoxy groups), by a C14-alkyl group which may be
terminally substituted by a cyclohexyl group, by a
straight-chained C24-alkyl group terminally substituted
by a methoxy or phenoxy group, or by a methyl group
which is substituted by a dimethylaminocarbonyl,
pyrrolidinocarbonyl or morpholinocarbonyl group;
B denotes an HNR11-C(=NH)- group wherein R11 denotes a
hydrogen atom, a ~C12-alkoxy)carbonyl group or a
benzyloxycarbonyl group, or B denotes an
R1-CO-O-(R2CR3)-0-CO-NH-C(=NH)- or (R40)PO(ORs)-NH-C~=NH)-
g p wherein R1, R2, R3, R4 and Rs are as hereinbefore
defined;
Y denotes a methylene group;
E denotes a carboxy group/ a (Cl6-alkoxy)carbonyl group
in which a methoxy moiety may be substituted by a phenyl
group, or E denotes a 1,3-dihydro-3-oxo-1-
isobenzofuranyloxycarbonyl group, an R6-C0-0-CHR7-0-C0-
- 14 -
group or an R~0-co- group, wherein R6, R7 ~nd R8 are as
hereinbefore defined and the shortest distance of the
group E from the first nitrogen atom of group B is at
least 10 bonds;
X1 denotes a bond, a methylene group which, provided that
it is not bound to the ring nitrogen atom of group A, is
bound to the adjacent X2 group via an oxygen atom or a
sulphonyl, -NR12-, -CO~NH- or -S02-NH- group, wherein R12
denotes a hydrogen atom or a methyl or acetyl group and
the carbonyl and sulphonyl group of the above~mentioned
-C0-NH- and -S02-NH- groups is linked to the group X2;
and
,,
X2 denotes a biphenylylene group optionally substituted
by a fluorine or chlorine atom or by a methyl, methoxy,
trifluoromethyl or methylsulphonyl group or by another
methyl group, or X2 denotes a phenylenecyclohexylene or
9,10-dihydrophenanthrenylene group or a fluorenylene
group in which the methylene group may be replaced by a
carbonyl group;
and the stereoisomers and tautomers, the mixtures and
the salts thereof.
More particularly preferred compounds according to the
invention include those of formula I wherein,
with the proviso that
(i) B denotes an R1-C0-0-(R2CR3)-0-C0-NH-C(=NH)- or
(R40)PO(ORs)-NH-C(=NH)- group or
E denotes an R6-C0-0-CHR7-0-C0- or R80-C0- group, or
(ii) B denotes an R1-C0-0-(R2CR3)-0-C0-NH-C(=NH)- or
(R40)PO(ORs)-NH-C(=NH)- group and
E denotes an R6-C0-0-CHR7-0-C0- or R80-C0- group,
J ~ 'J~ ~sJ ~
- 15 -
wherein
Rl den~tes a Cl4-alkyl group,
R2 denotes a hydrogen atom or a methyl yroup,
R3 denotes a hydrogen atom,
R4 and R~, which may be identical or different,
represent methyl or ethyl groups,
R6 denotes a C14-alkyl group, a cyclohexyl or phenyl
group, a C14-alkoxy group or a Cs7-cycloalkoxy
group,
R~ denotes a hydrogen atom or a methyl group and
R8 denotes a C58-cycloalkyl, (C58-cycloalkyl)methyl
or (C58-cycloalkyl)ethyl group, in which the
cycloalkyl moieties may additionally be substituted r~
by a C14-alkyl group or by a C14-alkyl group and 1
to 3 methyl groups, by a methoxy, ethoxy,
dimethylamino or diethylamino group and moreover,
in the above-mentioned cycloalkyl moieties, a
methylene group may be replaced by an oxygen atom
or by a methylimino or ethylimino group, with the
proviso that there are at least two carbon atoms
between the ring heteroatom and the next
heteroatom,
a cyclohexenyl or cyclohexenylmethyl group, in
which the above-mentioned cyclohexenyl moieties may
additionally be substituted by a methyl group, with
the proviso that the above-mentioned cyclohexenyl
moieties are not linked to the oxygen atom of the
adjacent -O-CO- group via a carbon atvm from which
a double bond starts,
-- 16 -
a C68-bicycloalkyl or C68-bicycloalkyl(C12-alkyl)
group, wherein the bicycloalkyl moieties may
additionally be substituted by 1 to 3 methyl
groups,
a C78-bicycloalkenyl or C78-bicycloalkenyl(C12-
alkyl) group, wherein the bicycloalkenyl moieties
may additionally be substituted by 1 to 3 methyl
groups, with the proviso that the above-mentioned
bicycloalkenyl moieties are not linked to the ~,
oxygen atom of the adjacent -0-C0- group via a ,~
carbon atom from which a double bond starts, ~:i
,,
a benzo(C34-cycloalkyl) group, .
a C3s-alkenyl or C~s-alkynyl group, with the proviso
that the above-mentioned alkenyl or alkynyl groups
are not linked to the oxygen atom of the adjacent
-0-C0- group via a carbon atom from which a double
or triple bond starts, or
a cinnamyl group;
A denotes a 2-pyrrolidinone ring optionally methyl-
substituted in the carbon skeleton;
B denotes an HNR11-C(=NH)- group wherein R11 represents a
hydrogen atom, a methoxycarbonyl, ethoxycarbonyl, or
benzyloxycarbonyl group or B denotes an
R1-C0-0-(R2CR3)-0-C0-NH-C(=NH)- or (R40)PO(ORs)-NH-C(=NH)-
group, wherein R1, ~2~ R3, R4 and R5 are as hereinbeforedefined;
Y denotes a methylene group;
E denotes a carboxy group, a (C15-alkoxy)carbonyl group,
an R6-C0-0-CHR7-0-C0- or R80-C0- group, wherein R6, R7 and
3 'j g~
-- 1.7 --
R8 are as hereinbefore defined and the shortest distance
of group E from the first nitrogen atom of group B is at
least 10 bonds;
Xl denotes a methylene group which, provided it is not
bound to the ring nitrogen atom of group A, is bound to
the adjacent X2 group via an oxygen atom or a sulphonyl,
-CO-NH- or -SO2-NH- group, in which the carbonyl and
sulphonyl groups of the above-mentioned -CO-NH- and
-SO2-NH- groups are linked to the group X2; and
X2 denotes a biphenylylene group which may be substituted
by a fluorine or chlorine atom, by a methyl or s-
trifluoromethyl group or by another methyl group; ~.
and the stereoisomers and tautomers thereof, the
mixtures and the salts thereof.
Yet more particularly preferred compounds according to
the invention include those of formula I wherein, 7`
with the proviso that
(i) B denotes an R1-CO-O-(R2CR3)-O-CO-NH-C(=NH)- or
(R4O)PO(OR5)-NH-C(=NH)- group or
E denotes an R6-CO-O-CHR7-O-CO- or R80-CO- group or
(ii) B denotes an R1-CO-O-(R2CR3)-O-CO-NH-C(=NH)- or
(R40)PO~ORs)-NH-C(=NH)- group and
E denotes an R6-CO-O-CHR7-O-CO- or R80-CO- group, wherein
R1 denotes a methyl group,
R2 denotes a hydrogen atom or a methyl group,
R3 denotes a hydrogen atom,
R4 and Rs each denote an ethyl group,
- ].8
R6 denotes a tert.butyl group or an ethoxy or
cyclohexyloxy group,
R7 denotes a hydrogen atom or a methyl group and
R~ denotes a cyclopentyl, cyclohexyl, cycloheptyl or
cyclohexylmethyl group;
A denotes a 2-pyrrolidinone ring;
B denotes an HNR11-C(=NH)- group wherein R11 represents a
hydrogen atom, a methoxycarbonyl or benzyloxycarbonyl
group, or B denotes an R1-CO-O-(R2CR3)-O-CO-NH-C(=NH)- or
(R40)PO(ORs)-NH-C(=NH)- group wherein R1, R2, R3, R4 and Rs
are as hereinbefore defined;
Y denotes a methylene group; ,~
E denotes a methoxycarbonyl group, an R6-CO-O-CHR7-O-CO- -~
or R80-CO- group, wherein R6, R7 and R8 are as
hereinbefore defined and the shortest spacing of group E .
from the first nitrogen atom of group B is at least 10
bonds;
X1 and X2 together denote a 4-biphenylyleneoxymethylene
group, wherein the group B in the 4'-position is linked
to the 4-biphenylyleneoxymethylene group, and the
methylene group of the 4-biphenylyleneoxymethylene group
is linked to a carbon atom of group A;
particularly those compounds wherein A, B, E, X1, X2 and
Y are as hereinbefore defined,
the group -Y-E is in position 3 and
the group B-X2-X1- is in position 5 of the 2-
pyrrolidinone ring;
and the stereoisomers, the tautomers, the mixtures and
- 19 -
the salts tilereo.
The present invention particularly relates to the
following compounds of formula I:
(3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone;
(3S,5S)-5-[[(4'-acetoxyethyl)oxycarbonylamidino-4-
biphenylyl]oxymethyl~-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone; .
(3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-biphenylyl)-
oxymethyl]-3-[[[1-(cyclohexyloxycarbonyloxy)ethyl]oxy-
carbonyl]methyl]-2-pyrrolidinone;
(3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-biphenylyl)-
oxymethyl]-3-[[[1-(ethyloxycarbonyloxy)ethyl]oxycarbo~
nyl]methyl]-2-pyrrolidinone;
(3S,5S)-5-[(4'-benzyloxycarbonylamidino~4-biphenylyl)-
oxymethyl]-3-[(pivaloyloxymethyloxycarbonyl)methyl]-2-
pyrrolidinone;
(3S,5S~-5-[(4'-methoxycarbonylamidino-4-biphenylyl)-oxy-
methyl]-3-[(pivaloyloxymethyloxycarbonyl)methyl]-2-
pyrrolidinone;
(3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-[[[1-
(cyclohexyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-2-
pyrrolidinone;
(3Sr5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-[[[1-
(ethyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-2-
pyrrolidinone;
r .., ~ 3 ~
- 20 -
(3S,5S~-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-[(piva-
loyloxymethyloxycarbonyl)methyl]-2-pyrrolidinon~;
(3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-[(cy-
clohexyloxycarbonyl)methyl]-2-pyrrolidinone;
(3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-[(cy-
clohexylmethyloxycarbonyl)methyl]-2-pyrrolidinone;
(3S,5S)-5-[(4'-amidino-4-biphenylyl1oxymethyl]-3-[(cy-
clopentyloxycarbonyl)methyl]-2-pyrrolidinone;
(3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-[(cy-
cloheptyloxycarbonyl)methyl]-2-pyrrolidinone;
(3S,5S)-3- [(cyclohexyloxycarbonyl)methyl]-5-[(4'-me-
thoxycarbonylamidino-4-biphenylyl)oxymethyl]-2-
pyrrolidinone; -
(3S,5S)-5-[[4'-O,O'-diethylphosphono)amidino-4-
biphenylyl]oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone;
and the salts thereof.
Viewed from a further aspect the invention provides a
process for the preparation of compounds of the
invention, said process com.prising at least one of the
following steps:
a) (to prepare compounds of formula I wherein B denotes
an R1-CO-O-(R2CR3)-O-CO-NH-C(=NH)- or HNR11-C(=NH)- group,
wherein R~, R2 and R3 are as hereinbefore defined, R
denotes a (C14-alkoxy)carbonyl group or a
phenoxycarbonyl. or benzyloxycarbonyl group and
additionally one of the two imino groups in the above-
mentioned groups may be substituted by a methyl group)
~J ~ 3 iJv
- 21 -
reacting a compounc1 ot` formula II
H2N - C(-NH) - X - X - A - Y E (II)
(wherein
A, E, X1, X2 and Y are as hereinbefore defined, whilst
additionally an amino or imino group in the above-
mentioned H2N-C(=NH)- group may be substituted by a
methyl group) with a compound of formula III
Z1 B1 (III)
(wherein
B1 denotes a (C1~-alkoxy)carbonyl group, a
phenoxycarbonyl group, a benzyloxycarbonyl group or an
R1-CO-O-(R2CR3)-O-CO- group in which R1, R2 and R3 are as
hereinbefore defined, and
Z1 denotes a nucleophilic leaving group such as a halogen -~
atom or an aryloxy group, e.g. a chlorine or bromine
atom or a p-nitrophenoxy group);
.
b) (to prepare compounds of formula I wherein E denotes
a di(C14-alkyl)aminocarbonylmethoxycarbonyl group, a
(C16-alkoxy)carbonyl group, wherein a methoxy moiety may
be substituted by a phenyl or pyridyl group, an ethoxy
moiety may be substituted by a phenyl or dimethoxyphenyl
group or in the 2-position by a morpholino or 2-oxo-l-
pyrrolidinyl group and an n-propoxy moiety may be
substituted by a phenyl group, or E denotes a l,3-
dihydro-3-oxo-l-isobenzofuranyloxycarbonyl,
R6-CO-O-CHR7-O-CO- or R~O-CO- group) reacting a compound
of formula IV
B - X2 - X1 - A - Y - COOH (IV)
(wherein
A, B, Xl, X2 and Y are as hereinbefore defined) with a
compound of formula V
t ;~ J~
- ~2 -
~ 2 ~ El (V)
(wherein
E1 denotes a di(C~4-alkyl)aminocarbonylmethyl group, a
C1~-alkyl group, wherein a methyl moiety may be
~ubstituted by a phenyl or pyridyl group, an ethyl
moiety by a phenyl or dimethoxyphenyl group or in the 2-
position by a morpholino or 2-oxo-l-pyrrolidinyl group
and an n-propyl moiety may be substituted by a phenyl
group, or E1 denotes a l,3-dihydro-3-oxo-l-
isobenzofuranyl, R6-CO-O-CHR7- or R8- group, wherein R6 to
R8 are defined as hereinbefore, and
Z2 denotes a nucleophilic leaving group such as a halogen
atom, e.g. a chlorine, bromine or iodine atom)i
c) (to prepare compounds of formula I wherein denotes
a di(C14-alkyl)aminocarbonylmethoxycarbonyl group, a
(C16-alkoxy)carbonyl group, in which a methoxy moiety ~,
may be substituted by a phenyl or pyridyl group, an ;,
ethoxy moiety by a phenyl or dimethoxyphenyl group or in
the 2-position by a morpholino or 2--oxo-l-pyrrolidinyl
group and an n-propoxy moiety may be substituted by a
phenyl group, or E denotes an R80-CO- group) reacting a
compound of formula IV
B - Xz - X1 ~ A - Y - COOH (IV)
(wherein
A, B, X1, X2 and Y are as hereinbefore defined) with a
compound of formula VI
HO - E2(V:[)
(wherein
E2 denotes a di(C14-alkyl)aminocarbonylmethyl group, a
C16-alkyl group, in which a methyl moiety may be
substituted by a phenyl or pyridyl group, an ethyl
moiety by a phenyl or dimethoxyphenyl group or in the 2-
position by a morpholino or 2-oxo-1-pyrrolidinyl group
and an n-propyl moiety may be substituted by a phenyl
group, or an R8 group, wherein R~ is as hereinbefore
defined);
d) (to prepare compounds of formula I wherein B denotes
an (R40)PO(ORs)-NH-C(=NH)- group, wherein R4 and R5, which
may be identical or different, denote Cl4-alkyl groups,
benzyl or phenyl groups and additior,ally one of the two
imino groups in the above-mentioned group may be
substituted by a methyl group) reacting a compound of
formula II
Tl2N - C(=NH) - Xz - Xl - A - Y - E (II)
(wherein
A, E, X1, Xz and Y are defined as hereinbefore, whilst
additionally an amino or imino group in the above-
mentioned H2N-C(=NH)- group may be substituted by a
methyl group) with a compound of formula VII
(R4 r 0) PO (ORs l ) ~Z3 (VII )
(wherein
R4' and Rs'/ which may be identical or different, denote
C14-alkyl groups, benzyl or phenyl groups and
Z3 denotes a nucleophilic leaving group such as a cyano
group or a halogen atom, e.g. a chlorine or bromine
atom~;
e) resolving a compound of formula I thus obtained into
the stereoisomers thereof;
f) converting a compound of formula I thus obtained into
a salt thereof, more particularly for pharmaceutical use
into a physiologically acceptable salt thereof with an
inorganic or organic acid or base, or converting a salt
~ 3~~
- 24 -
of a compound of formula I into the free compound; and
g) performing a process as defined in any one of steps
(a) to (f) above on a corresponding protected compound
and subsequently removing the protecting group used.
The reaction of step (a) is conveniently carried out in
a solvent such as tetrahydrofuran, methylene chloride,
chloroform, ethyl acetate or dimethylformamide,
expediently in the presence of a base such as sodium
carbonate, potassium carbonate or sodium hydroxide ,,
solution or in the presence of a tertiary organic base
such as triethylamine, N-ethyl-diisopropylamine, N-
methyl-morpholine or pyridine, which may simultaneously
serve as solvent, at temperatures between -30 and 100C,
but preferably at temperatures between -10 and 60C.
The reaction of step (b) is conveniently carried out in
a solvent such as methylene chloride, tetrahydrofuran,
dioxane, dimethylsulphoxide or dimethylformamide,
optionally in the presence of a reaction accelerator
such as sodium or potassium iodide and preferably in the
presence of a base such as sodium carbonate, potassium
carbonate or sodium hydroxide solution or in the
presence of a tertiary organic base such as N-ethyl-
diisopropylamine or N-methyl-morpholine, which may
simultaneously be used as solvent, or optionally in the
presence of silver carbonate or silver oxide, at
temperatures between -30 and 100C, but preferably at
temperatures between -10 and 80C.
The esterification of step (c) is conveniently carried
out in a suitable solvent or mixture of solvents, e.g.
in a corresponding alcohol such as methanol, ethanol,
isopropanol or cyclohexanol, methylene chloride,
tetrahydrofuran, dioxane, pyridine, toluene or
dimethylformamide in the presence of an acid-activating
- 25 -
and~or dehydrating agent such as hydrogen chloride,
conc. sulphuric acid, thionyl chloride, titanium
tetrachloride, trimethylchlorosilane,
ethylchloroformate, carbonyldiimidazole or N,N'-
dicyclohexyl-carbodiimide or the isourea esters thereof,
optionally in the presence of a reaction accelerator
such as copper chloride, at temperatures between 0 and
100C, but preferably at temperatures between 20C and
80C.
The reaction of step (d) is conveniently carried out in
a solvent or mixture of solvents such as
tetrahydrofuran, methylene chloride, chloroform, ethyl
acetate or dimethylformamide, expediently in the
presence of an inorganic base such as sodium carbonate, ~;~
potassium carbonate or sodium hydroxide solution or in ~.'
the presence of a tertiary organic base such as
triethylamine, N-ethyl-diisopropylamine, N-methyl-
morpholine or pyridine, which may simultaneously serve :~
as solvent, at temperatures between -30C and 100C, but
preferably at temperatures between -10C and 60C.
In the reactions described hereinbefore, any reactive
groups present such as hydroxy, carboxy, phosphono, 0-
methyl-phosphono, O-ethyl-phosphono, amino, alkylamino,
imino or amidino groups may be protected during the
reaction by means of conventional protecting groups
which are cleaved again after the reaction.
For example, protective groups for a hydroxy group
include trimethylsilyl, acetyl, benzoyl, tert.butyl,
trityl, benzyl and tetrahydropyranyl groups,
protecting groups for a carboxyl group include
trimethylsilyl, methyl, ethyl, tert.butyl, benzyl and
tetrahydropyranyl groups,
the protecting group for an amidino group may be the
r
-- 26
benzyloxycarbonyl group,
the protecting group for a phosphono group may be a
phenyl, methyl, ethyl or benzyl group, and
the protecting group for an amino, alkylamino or imino
group may be an acetyl, benzoyl, ethoxycarbonyl, tert~-
butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl
or 2,4-dimethoxybenzyl group and for the amino group a
phthalyl group may also be considered.
The optional subsequent cleaving of a protecting group
may, for example, be carried out hydrolytically in an
aqueous solvent, e.g. in water, isopropanol/water,
tetrahydrofuran/water or dioxane/water, in the presence
of an acid such as trifluoroacetic acid, hydrochloric
acid or sulphuric acid or in the presence of an alkali
metal base such as sodium hydroxide or potassium
hydroxide or aproticly, e.g. in the presence of
icdotrimethylsilane, at temperatures between -10 and
100C, preferably at temperatures between 0 and 60C.
However, a benzyl, methoxybenzyl or benzyloxycarbonyl
group may be cleaved hydrogenolytically, for example,
using hydrogen in the presence of a catalyst such as
palladium/charcoal in a solvent such as methanol,
ethanol, ethyl acetate or glacial acetic acid,
optionally with the addition of an acid such as
hydrochloric acid, at temperatures between 0 and 50C,
but preferably at ambient temperature, under a hydrogen
pressure of 1 to 7 bar, preferably 3 to 5 bar.
A methoxybenzyl group may also be cleaved in the
presence of an oxidising agent such as cerium(IV)-
ammonium nitrate, in a solvent such as methylene
chloride, acetonitrile or acetonitrile/water, at
temperatures between 0 and 50C, but preferably at
~ J i
- 27 -
ambient temperature.
However, a 2,4-dimethoxybenzyl group is preferably
cleaved in trifluoroacetic acid in the presence of
anisole.
A tert.butyl or tert.butyloxycarbonyl group is
preferably cleaved by treating with an acid such as
trifluoroacetic acid or hydrochloric acid, optionally
using a solvent such as methylene chloride, dioxane or
etherO
The cleaving of only one alkyl group from an 0,0'- ~-
dialkylphosphono group is preferably carried out using -
sodium iodide in a solvent such as aceton~
ethylmethylketone, acetonitrile or dimethylformamide, at
temperatures between 40 and 150C, but preferably at
temperatures between 60 and lO0C.
The cleaving of both alkyl groups from an O,0'-
dialkylphosphono group is carried out, for example, with
iodotrimethylsilane, bromotrimethylsilane or chloro-
trimethylsilane/sodium iodide, in a solvent such as
methylene chloride, chloroform or acetonitrile, at
temperatures between 0C and the boiling temperature of
the reaction mixture, but preferably at temperatures
between 20 and 60C.
The cleaving of a phthalyl group is preferably carried
out in the presence of hydrazine or a primary amine such
as methylamine, ethylamine or n-butylamine, in a solvent
such as methanol, ethanol, isopropanol, toluene/water or
dioxane, at temperatures between 20 and 50C.
The compounds of formula I obtained may be resolved into
their enantiomers and/or diastereomers. Thus, for
example, cis/trans mixtures may be resolved into their
3 ?~ ~
- 2~3 -
cis and trans isomers, and compounds having at least one
optically active carbon atom may be resolved into their
enantiomers.
Thus, for e~ample, the cis/trans mixtures obtained may
be resolved by chromatography into the Ci5 and trans
isomers thereof and the compounds of formula I obtained,
which occur in racemate form, may be separated by
methods ~nown per se (see Allinger N. L. and Eliel E. L.
in "Topics in Stereochemistry", Vol. ~, Wiley
Interscience, lg71) into their optical antipodes and
compounds of formula I having at least 2 asymmetric
carbon atoms may be separated on the basis of their
physical-chemical differences using known methods, e.g.
by chromatography and/or fractional crystallisation, -~
into the diastereomers thereof which, if they occur in
racemic form, may subsequently be separated into the
enantiomers as mentioned above.
The separation of enantiomers is preferably effected by
column separation on chiral phases or by
recrystallisation from an optically active solvent or by
reacting with optically active substances, especially
acids and the activated derivatives or alcohols thereof,
which form salts or derivatives, such as for example
esters or amides, with the racemic compound, and
separation of the diastereomeric salt or derivative
mixture thus obtained, e.g. on the basis of their
different solubilities, whilst the free antipodes may be
released from the pure diastereomeric salts or
derivatives by the action of suitable agents.
Particularly common, optically active acids include, for
example, the D- and L-forms of tartaric acid or
dibenzoyltartaric acid, di-o-tolyl tartaric acid, malic
acid, mandelic acid, camphorsulphonic acid, glutamic
acid, aspartic acid or quinic acid. Examples of an
optically active alcohol include (~)- or (-)-menthol and
v iJ
- 29 -
examples of an optically active acyl group in amides
include (~)- or (-)-menthyloxycarbonyl.
Moreover, the compounds of formula I obtained may be
converted into the salts thereof, partieularly for
pharmaeeutical use into the physiologieally aeeeptable
salts thereof with inorganie or organie aeids. Examples
of suitable aeids for this purpose inelude hydroehlorie
aeid, hydrobromic aeid, sulphurie aeid, phosphorie aeid,
aeetie acid, fumarie aeid, sueeinie aeid, laetie aeid,
citrie acid, tartaric acid or maleic aeid.
In addition, the new eompounds of formula I thus
obtained, if they contain an aeid group sueh as a
earboxyl or phosphono group, may subse~uently, if
desired, be eonverted into the addition salts thereof
with inorganie or organie bases, more partieularly, for
pharmaeeutieal use, into the physiologically aeceptable
addition salts thereof. Examples of suitable bases for ~;~
this purpose include sodium hydroxide, potassium -~
hydroxide, ammonia, eyelohexylamine, ethanolamine,
diethanolamine and triethanolamine.
The eompounds used as starting materials are known from
the literature in some eases or may be obtained by
methods known from the literature as deseribed in
Examples I to X.
For example, a eompound of formula II may be obtained by
reaeting a eorresponding nitrile with an alcohol sueh as
methanol, ethanol or propanol in the presence of an aeid
sueh as hydroehlorie aeid or by reaeting a corresponding
amide with a trialkyloxonium salt sueh as
triethyloxonium-tetrafluoroborate, conveniently in a
solvent sueh as methylene chloride, tetrahydrofuran or
dioxane, or by reacting a eorresponding nitrile with
hydrogen sulphide, conveniently in a solvent such as
- 30 -
pyridine or dimethylformamide, and subsequent alkylation
of the resulting thioamide with an alkyl halide and
subsequent reaction of an iminoester or iminothioester
thus obtained with ammonia, methylamine or with a
corresponding acid addition salt such as ammonium
carbonate or ammonium acetate.
For example, a compound of formula IV may be obtained by
cleaving a corresponding ester in an aqueous solvent,
e.g. in water, water/tetrahydrofuran or water/methanol,
in the presence of an alkali metal base such as sodium
hydroxide or potassium hydroxide or in the presence of
an acid such as hydrochloric acid, sulphuric acid or
trifluoroacetic acid. A compound of formula IV wherein ;1
B denotes an amidino group substituted by an ;~;
alkoxycarbonyl or benzyloxycarbonyl group may be
obtained for example by reacting a corresponding amidino
compound with a corresponding alkoxyrarbon~vl or ~b~
benzyloxycarbonyl halide before the above-mentioned
ester cleaving.
The new cyclic imino derivatives of formula I and the
salts thereof, particularly the physiologically
acceptable salts thereof with inorganic or organic acids
or bases, have valuable properties. Thus, the new
compounds of formula I have valuable pharmacological
properties and in addition to having an inhibitory
effect on inflammation and bone degradation, have, in
particular, antithrombotic, antiaggregatory and tumour-
or metastasis-inhibiting effects.
By way of example, the compounds of formula I w~re
investigated for their biological effects as follows:
The inhibition of thrombocyte aggregation after oral
administration of the test substance is determined ex
vivo on Rhesus monkeys.
~ VVJ
- 31 -
Immediately before the oral administration of the test
substance suspended in Natrosol, a blood sample is taken
from the cubital vein of the animals as a reference
value. At specific times after the administration of
the substance fresh blood samples are taken and examined
as iollows:
The whole blood mixed with 3.14% sodium citrate in a
ratio by volume of l:lo is centrifuged at 200 g for 15
minutes. The supernatant platelet-rich plasma is
carefully removed. From the erythrocyte-rich sediment,
the platelet-impoverished plasma is obtained as
supernatant by centrifuging at 4000 g for lO minutes.
The thrombocyte aggregation induced in these ex vivo
samples by means of collagen (Hormonchemie, Munich;
2 ~g/ml final concentration in the platelet rich plasma) ~!
is measured photometrically using the method of Born and ~j
Cross (J. Physiol. 170:397 (1964)). The maximum light
transmittance of the platelet rich plasma measured after
collagen stimulation is compared with the reference
value in order to determine the inhibition of
aggregation at the various times of blood sampling after
the administration of the substance, in relation to the
reference value.
The compounds of Examples 1 and 3 inhibit the collagen-
induced thrombocyte aggregation ex vivo after the oral
administration of 1 mg/kg for more than 8 and for more
than 4 hours, respectively.
After oral administration of 3 mg/kg the compound of
Example 4 inhibits the collagen-induced thrombocyte
aggregation ex vivo for longer than 8 hours.
The compounds according to the invention are well
tolerated since, for example, the approximate LDso of the
~9~
- 32 -
compounds of Examples 1 and 3 in the mouse is above
300 mg/kg and that o~ the compound of Example 4 is above
100 mg/kg, after oral administration in each case.
In the light of their inhibitory effeet on cell-eell or
eell-matrix interactions, the new eyelic imino
derivatives of formula I and the physiologieally
acceptable addition salts thereof are suitable for
combating or preventing diseases in which smaller or
larger cell aggregates oeeur or in whieh eell-matrix
interactions play a part, e.g. in treating or preventing
venous and arterial thrombosis, cerebrovascular
diseases, lung embolism, cardiac infarction,
arteriosclerosis, osteoporosis and the metastasis of
tumours and in the treatment of genetically caused or
aequired disorders of eell interactions with one another
or with solid struetures. They are also suitable for
parallel therapy in thrombolysis with fibrinolyties or
vascular interventions sueh as transluminal angioplasty
or in the treatment of shoek, psoriasis, diabetes and
inflammation.
Thus, viewed Erom a further aspeet the present invention
provides a pharmaceutieal eomposition eomprising a
compound of formula I or a physiologieally aeeeptable
salt thereof together with at least one physiologically
acceptable carrier or excipient.
Viewed from a still further aspect the invention
provides the use of a compound of formula I or a
physiologically acceptable salt thereof for the
manufacture of a therapeutic agent suitable for
eombating or preventing diseases in which smaller or
larger cell aggregates oceur or in whieh cell-matrix
interactions play a part.
In particular, the invention provides the use of a
3 t.~ ~ V~
- 33 -
compound of formula I or a physiologically acceptable
salt thereof for the manufacture of a therapeutic agent
for treating or preventing venous and arterial
th ombosis, cerebrovascular diseases, lung embolism,
cardiac infarction, arteriosclerosis, osteoporosis and
the metastasis of tumours and in the treatment of
genetically caused or acquired disorders of cell
interactions with one another or with solid structures.
Viewed from a yet still further aspect the invention
provides a method of treatment of the human or non-human
animal body to combat or prevent diseases in which
smaller or larger cell aggregates occur or in which
cell-matrix interactions play a part, said method
comprising administering to said body a compound of
formula I or a physiologically acceptable salt thereof.
In particular, the invention provides a method of
treatment of the human or non-human animal body to
combat or prevent venous and arterial thrombosis,
cerebrovascular diseases, lung embolism, cardiac
infarction, arteriosclerosis, osteoporosis and the
metastasis of tumours and in the treatment of
genetically caused or acquired disorders of cell
interactions with one another or with solid structures,
said method comprising adminis~ering to said body a
compound of formula I or a physiologically acceptable
salt thereof.
For treating or preventing the diseases mentioned above
the dosage is between 0.1 ~g and 30 mg/kg of body
weight, preferably 1 ~g to 15 mg/kg of body weight,
given in up to 4 doses per day. For this purpose the
compounds of formula I produced according to the
invention, optionally in con~unction with other active
substances such as thromboxane receptor antagonists and
thromboxane synthesis inhibitors or combinations
) 7J
- 3~ -
thereof, serotonill antagonists, ~-receptor antagonists,
alkylnitrates such as glycerol trinitrate, phospho-
diesterase inhibitors, prostacyclin and the analogues
thereof, fibrinolytics such as tPA, prourokinase,
urokinase, streptokinase, or anticoagulants such as
heparin, dermatane sulphate, activated protein C,
vitamin K antagonists, hirudin, inhibitors of thrombin
or other activated clotting factors, may be incorporated
together with one or more inert conventional carriers
and/or diluents, e.g. with corn starch, lactose,
sucrose, microcrystalline cellulose, magnesium stearate,
polyvinylpyrrolidone, citric acid, tartaric acid, water,
water/ethanol, water/glycerol, water/sorbitol,
water/polyethyleneglycol, propyleneglycol,
stearylalcohol, carboxymethylcellulose or fatty
substances such as hard fat or suitable mixtures ~
thereof, into conventional galenic preparations such as ;`~,
plain or coated tablets, capsules, powders, suspensions,
solutions, sprays or suppositories.
The following non-limiting Examples are provided to
illustrate the invention. All percentages and ratios
are by weight, other than eluant or solvent ratios which
are by volume.
~3~ 3 ~
- 35 -
Startinq comE_unds.
Example I
(S)-1-(Benzyloxycarbonyl)-5-[(trityloxy)methyl]-2-
pyrrolidinone
A solution of 160 g of (S)-5-[(trityloxy)methyl]-2-
pyrrolidinone in 1600 ml of dry tetrahydrofuran is mixed
within 35 minutes at -65~C with 179 ml of a 2.5 M
solution of butyllithium in hexane. After 10 minutes at
-65C, a solution of 66.8 ml of benzylchloroformate in
100 ml of dry tetrahydrofuran is added dropwise and the
resulting mixture is stirred for one hour. Then 200 ml
of saturated saline solution are added and the
tetrahydrofuran is eliminated by rotary evaporation.
The residue is distributed between 3.5 litres of ethyl
acetate and 200 ml of water, the organic phase is
separated off and washed twice each with water and
saline solution. The organic phase is separated off,
dried and concentrated by rotary evaporation. The crude
product is recrystallised from a little ethanol.
Yield: 181 g ~B2% of theory),
Melting point: 103-105C
R~ value: 0.53 (silica gel; cyclohexane/ethyl acetate =
2:1)
Calculated: C 78.19 H 5.95 N 2.85
Found: 78.34 6.00 3.10
Example II
(3S,5S)-l-(Benzyloxycarbonyl)-3-[(tert.butyloxy-
carbonyl)methyl]-5-[(trityloxy)methyl]-2-pyrrolidinone
To 20.0 g of (S)-l-(benzyloxycarbonyl)-5-[(trityloxy)-
methyl]-2-pyrrolidinone in 200 ml of dry
tetrahydrofuran, 40.6 ml of a 1 molar solution of
f~ J 3 ~
- 36 -
lithium he~amethyldisilazide in tetrahydrofuran are
added dropwise at -65~C. After lO minutes a solution of
6.57 ml of tert.butylbromoacetate in 20 ml of dry
tetrahydrofuran is added dropwise. After 2 hours'
stirring at -65C the mixture is heated to ooc and 20 m
of a saturated aqueous ammonium chloride solution are
added. The mixture is evaporated down in vacuo, the
residue is mixed with 500 ml of ethyl acetate and
extracted twice with water and once with saturated
saline solution. The organic phase is dried,
concentrated by rotary evaporation and the residue is
purified by chromatography over a silica gel column with
cyclohexane/ethyl acetate = 4:1.
Yield: 20.0 g (81% of theory),
Rf value: 0.66 (silica gel; cyclohexane/ethyl acetate =
2:1)
Calculated: C 75.35 H 6.49 N 2.31
Found: 75.17 6.65 2.50
Example III
(3S,5S)-3-[(tert.Butyloxycarbonyl)methyl]-5-
hydroxymethyl-2-pyrrolidinone
-
246 g of (3S,SS)-1-(benzyloxycarbonyl)-3-
[(tert.butyloxycarbonyl)methyl]-5-[(trityloxy)methyl]-2-
pyrrolidinone in 1.6 litres of tert.butanol are
hydrogenated for 1~ days at 50C under a hydrogen
pressure of 5 bar with 50 g of palladium (10% on
activated charcoal). Then the mixture is diluted with
acetone, the catalyst is filtered off and the filtrate
is evaporated down. The residue is stirred in 3 batches
with a total of 2 litres of petroleum ether. The
remaining oil is dried ln vacuo.
Yield: 77.8 g (84% of theory),
Rf value: 0.43 (silica gel; ethyl acetate/methanol =
15:1)
,f ~.~ .,
-- 37 --
F.xample_IV
(3S,5S)-3-[(tert.Butyloxycarbonyl)methyl]-5-
[(methanesulphonyloxy)methyl]-2-pyrrolidinone
To 2.7 q of (3S,5S)-3-[(tert.butyloxycarbonyl)methyl]-5-
hydroxymethyl-2-pyrrolidinone in 25 ml of methylene
chloride are added, at 0C, 1.76 g of methanesulphonic
acid chloride, followed by 1.7 g of triethylamine, by
dropwise addition. After one hours' stirring whilst
cooling with ice and 2 hours' stirring at ambient
temperature the mixture is combined with ice water, the
organic phase is separated off, washed twice with water,
dried and evaporated down. After recrystallisation from
ethyl acetate, 2.35 g (65% of theory) are obtained.
Melting point: 114-116C
Rf value: 0.47 (silica gel; toluene/ace~-one = 1:3)
Calculated: C 46.89 H 6.89 N 4.56 S 10.43
Found: 46.90 6.7g 4.84 10.17
Example V
(3S,5S)-3-[(tert.Butyloxycarbonyl)methyl]-5-[(4'-cyano-
4-biphenylyl)oxymethyl]-2-pyrrolidone
3.4 g of potassium tert.butoxide are added to 5.9 g of
4'-cyano-4-hydroxybiphenyl in 150 ml of dry
dimethylformamide. After one hours' stirring at ambient
temperature, 9.2 g of (3S,5S)~3-[(tert.butyloxy-
carbonyl)methyl]-5-[(methanesulphonyloxy)methyl]-2-
pyrrolidinone are added and the mixture is stirred for 3
days at ambient temperature. The reaction mixture is
added to 550 ml of water and the mixture is stirred for
half an hour. The precipitate is suction filtered and
recrystallised twice from 95~ ethanol.
Yield: 8.35 g (68~ of theory),
Melting point: lS9-160C
~V~J
- 38 -
Rf value: 0.64 (silica gel; ethyl acetate)
Example VI
(3S,5S)-5-[(4'-Amidino-4-biphenylyl)oxymethyl]-3-
[(methoxycarbonyl)methyl]-2-pyrrolidinone-hydrochloride
0.9 g of (3S,5S)-3-[(tert.butyloxycarbonyl)methyl]-5-
[(4'-cyano-4-biphenylyl)oxymethyl]-2-pyrrolidinone are
added to 50 ml of dry methanol, which has been saturated
with hydrogen chloride gas whilst cooling with ice. The
reaction mixture is covered with some petroleum ether
and stirred overnight. It is concentrated by
evaporation, the residue is combined with ll ml of
methanol and a pH of about 9 is achieved with conc.
aqueous ammonia, whilst cooling with ice. After 3 days'
stirring at ambient temperature the mixture is
evaporated down, the residue is stirred with 100 ml of
methylene chloride/methanol (85:15), then filtered and
the filtrate is concentrated by evaporation. The
residue is stirred with methylene chloride/tert.butyl-
methylether and the solid matter is suction filtered and
dried.
Yield: 0.8 g (87% of theory)
Rf value: 0.45 (Reversed Phase silica gel (RP8);
methanol/5% aqueous saline solution =
3:2)
Exam~le VII
(3S,5S)-5-[(4'-Methoxycarbonylamidino-4-biphenylyl)-
oxymethyl]-3-[(methoxycarbonyl)methyl]-2-pyrrolidinone
. _
To a suspension of 2.0 g of (3S,5S)-5-[(4'-amidino-4-
biphenylyl)oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone hydrochloride in 200 ml of methylene
- 39 -
chloride are added 480 mg of methyl chloroformate and
then 50 ml of 0.2 molar sodium hydroxide solution are
added dropwise at ambient temperature, with vigorous
stirring. The organic phase is separated off, washed
twice with water, dried and evaporated down. The
residue is chromatographed over a silica gel column with
ethyl acetate and ethyl acetate/methanol (95:5). The
product is heated to boiling with 15 ml of ethyl
acetate, the suspension is cooled and the solids are
suction filtered and dried.
Yield: 430 mg (21% of theory),
Melting point: 183-184C (decomp.)
Rf value: 0 47 (silica gel; ethyl acetate/methanol =
97:3)
Calculated: C 62.86 H 5.73 N 9.56
Found: 62.60 5.85 9.55
The following is obtained analogously:
(1) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone
(Carried out with benzylchloroformate in
tetrahydrofuran)
Rf value: 0.37 (silica gel; ethyl acetate)
Example VIII
(3S,5S)-3-Carboxymethyl-5-[(4'-methoxycarbonylamidino-4-
biphenylyl)oxymethyl]-2-pyrrolidinone
440 mg of (3S,5S)-5-[(4'-methoxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone are suspended in a mixture of 8 ml of
tetrahydrofuran and 4 ml of water and 0.75 ml of 4N
sodium hydroxide solution are added, with stirring, at
ambient temperature. After 30 minutes' stirring at
- ~o -
ambient temperature the reaction mixture is acidified
with glacial acetic acid and diluted with some water.
The precipitate is suction filtered, washed with water
and dried.
Yield: 320 mg (75% of theory)
Rf value: 0.68 (Reversed Phase silica gel (RP8);
methanol/5% aqueous saline solution =
6:4)
The following is obtained analo~ously:
(1) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-carboxymethyl-2-pyrrolidinone
Melting point: 202C (decomp.)
R~ value: 0.44 (Reversed Phase silica gel (RP8);
methanol/5% aqueous saline solution =
6:4)
Example IX
(3S,5S)-5-[(4'-Amidino-4-biphenylyl)oxymethyl]-3-
carboxymethyl-2-pyrrolidinone
To 20 g of (3S,5S)-5-[(4'-amidino-4-biphenylyl)-
oxymethyl]-3-[(methoxycarbonyl)methyl]-2-pyrrolidinone-
hydrochloride in 200 ml of methanol are added 37.5 ml of
4N sodium hydroxide solution and the mixture is stirred
for 6 hours at ambient temperature. 10.7 y of ammonium
chloride are added, followed by a further 200 ml of
water after a few minutes, and the mixture is stirred
for 45 minutes in an ice/water bath. The precipitate is
suction filtered, washed twice each with methanol and
water/methanol (2:1) and dried.
Yield: 15.2 g (86% of theory),
Melting point: 292-294C (decomp.)
Rf value: 0.63 (Reversed Phase silica gel (RP8);
methanol/10% aqueous saline solution = 6:4)
~1~tlt3V ~'
- 91 -
Calculated: C 6~.38 ~i 5.7~ N 11.44
Found:65.20 5.80 11.54
~X
(3S,5S)-5-[(4'-Amidino-4-biphenylyl)o~ymethyl]-3-
[(neopentyloxycarbonyl)methyl]-2-pyrrolidinone x 1.1 HCl
x 0.5 water
.
Hydrogen chloride gas is passed, with stirring, over a
suspension of 1.1 g of (3S,SS)-5-[(4'-amidino-4-
biphenylyl)oxymethyl]-3-carboxymethyl-2-pyrrolidinone in
10 g of liquid neopentyl alcohol. After 20 minutes the
reaction mixture is stirred for another hour at 60C.
The reaction mixture is mixed with diethylether after
cooling and the precipitate is suction filtered and
dried in a desiccator over potassium hydroxide and conc.
sulphuric acid. The crude product is taken up in
methylene chloride, with gentle heating, filtered and
the filtrate is evaporated down. The residue is stirred
with acetone/diethylether, suction filtered, washed with
diethylether and dried over sodium hydroxide and conc.
sulphuric acid in a desiccator.
Yield: 1.14 g (80% of theory),
Rf value: 0.24 (Reversed Phase silica gel (RP8);
methanol/5% aqueous saline solution -
6:4)
Calculated: C 61.70 H 6.86 N 8.63 Cl 8.01
Found: 61.98 7.14 8.43 7.87
Mass spectrum: (M~H)+ = 438
The following are obtained analogously:
(1) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
~(isobutyloxycarbonyl)methyl]-2-pyrrolidinone-
hydrochloride
Rf value: 0.26 (Reversed Phase silica gel (RP8);
f..J t~
- 42 -
methanol/5% aqueous saline solution =
6:~)
Mass spectrum: (M+H)+ = 424
(2) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(benzyloxycarbonyl)methyl]-2-pyrrolidinone x 1.05 HCl x
0.5 water
Rf value: 0.19 (Reversed Phase silica gel (RP8);
methanol/5~ aqueous saline solution =
6:4)
Calculated: C 64.24 H 5.80 N 8.32 Cl 7.37
Found: 64.38 5.73 8.20 7.42
Mass spectrum: (M+H)+ = 458
(3) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
t(ethyloxycarbonyl)methyl]-2-pyrrolidinone-hydrochloride
Rf value: 0.54 (Reversed Phase silica gel (RP8);
methanol/10% aqueous saline solution =
6:4)
~4) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(isopropyloxycarbonyl)methyl]-2-pyrrolidinone-
hydrochloride
Rf value: 0.49 (Reversed Phase silica gel (RP8);
methanol/10% aqueous saline solution =
6:4)
(5) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[~propyloxycarbonyl)methyl]-2-pyrrolidinone-
hydrochloride
i 't.~i~ V~
- ~.3 -
_xcm~le l
(3S,5S)-5-[(4'-Acetoxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone
1.06 g of (3S,5S)-5-[(4'-amidino-4-
biphenylyl~oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone-hydrochloride, 800 mg of acetoxymethyl-(4-
nitrophenyl)carbonate and 726 mg of N-ethyl-
diisopropylamine are stirred in 80 ml of methylene
chloride for 20 hours at ambient temperature. The
reaction mixture is washed with water, with 40 ml of
O.lN sodium hydroxide solution and again with water.
Then the organic phase is separated off, dried and
evaporated down. The residue is chromatographed o~er a
silica gel column with methylene chloride/methanol
(97:3). The product is briefly stirred with
tert.butylmethylether in the warm, then suction filtered
and dried.
Yield: 380 mg (30% of theory),
Rf value: 0.25 (silica gel; methylene chloride/methanol
= 95:5)
Calculated: C 60.36 H 5.~7 N 8.45
Found: 60.33 5.87 8.07
Mass spectrum: (M+H)+ = 498
The following are obtained analogously:
(1) (3S,5S)-5-[[4'-(1-acetoxyethyl)oxycarbonylamidino-4-
biphenylyl]oxymethyl~-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone x 0.75 water
Rf value: 0.36 (silica gel; methylene chloride/acetone =
65:35)
Calculated: C 59.48 H 5.86 N 8.00
Found: 59.38 5.73 8.02
Mass spectrum: (M+H)+ = 512
~ 44 ~ ~n~ vo~
(2) (3S,5S)-5-[[4'-(1-acetoxyethyl)oxycarbonylamidino-4-
biphenylyl]oxymethyl]-3-[(ethoxycarbonyl)methyl]-2-
pyrrolidinone
(3) (3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(ethoxycarbonyl)methyl]-2-
pyrrolidinone
(4) (3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4
biphenylyl)oxymethyl]-3-[(isopropoxycarbonyl)methyl3-2-
pyrrolidinone
(5) (3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(benzyloxycarbonyl)methyl]-2-
pyrrolidinone
(6) (3S,5S)-3-[(methoxycarbonyl)methyl]-5-[(4'-
pivaloyloxymethyloxycarbonylamidino-4-biphenylyl)-
oxymethyl]-2-pyrrolidinone
(7) (3S,5S)-3-[(ethoxycarbonyl)methyl]-5-[(4'-
pivaloyloxymethyloxycarbonylamidino-4-biphenylyl)-
oxymethyl]-2-pyrrolidinone
(8) (3S,5S)-5-[(4'-butyryloxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone
(9) (3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl)-3-[(propoxycarbonyl)methyl]-2-
pyrrolidinone
(10) (3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(pivaloyloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone
(11) (3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4-
~ ~3 ~ 9
- ~5 -
biphenylyl)sulp}lonylmethyl~-3-[(methoxycarbonyl)methyl]-
1-(3-phenylpropyl)-2-pyrrolidinone
(12) (3S,5S)-3-[(cyclohexyloxycarbonyl)methyl]-5-[(4'-
propionyloxymethyloxycarbonylamidino-4-biphenylyl)-
oxymethyl]-2-pyrrolidinone
(13) (3S,5S)-5-[(4'-isobutyryloxymethyloxycarbonyl-
amidino-4-biphenylyl)oxymethyl]-3-[(methoxycarbonyl)-
methyl]-2-pyrrolidinone
(14) (3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3--[(neopentyloxycarbonyl)methyl]-
2-pyrrolidinone
(15) (3S,5S)-5-[(4'-acetoxymethyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(isobutyloxycarbonyl)methyl]-2-
pyrrolidinone
Example 2
(3S,5S)-5-[(4'-Benzyloxycarbonylamidino-4-biphenylyl)-
oxymethyl]-3-[[[1-(cyclohexyloxycarbonyloxy)ethyl]oxy-
carbonyl]methyl]-2-pyrrolidinone
900 mg of (3S,5S)-5-[(4' benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-carboxymethyl-2-pyrrolidinone,
750 mg of (l-chloroethyl)-cyclohexylcarbonate, 500 mg of
potassium carbonate and a spatula tip of sodium iodide
are stirred in 8 ml of dimethylsulphoxide at ambient
temperature for 3 days. The mixture is combined with
ice water and the precipitate is suction filtered and
washed with water. The moist precipitate is taken up in
ethyl acetate, dried with magnesium sulphate, filtered
and concentrated by rotary evaporation. The residue is
stirred with diethylether, the solid product is suction
filtered, washed with diethylether and dried.
9~
- 46 -
Yield: 1.5 g (95% of theory),
Rf value: 0.60 (silica gel; methylene chloride/acetone =
65:35)
The following are obtained analogously:
(1) (3S,5S~-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[~[1-(ethyloxyearbonyloxy)ethyl]
oxyearbonyl]methyl]-2-pyrrolidinone
Rf value: 0.43 (siliea gel; methylene ehloride~aeetone =
65:35)
(2) (3S,5S)-5-[(4'-benzyloxyearbonylamidino-4-
biphenylyl)oxymethyl]-3-[(pivaloyloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone
Rf value: 0.52 (silica gel; methylene chloride/acetone =
65:35)
(3) (3S,5S~-3-[(acetoxymethyloxyearbonyl)methyl~-5-[(4'-
benzyloxyearbonylamidino-4-biphenylyl)oxymethyl]-2-
pyrrolidinone
(4) (3S,5S)-5-[(4'-benzyloxyearbonylamidino-4-
biphenylyl)oxymethyl]-3-~(butyryloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone
(5) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[(isobutyryloxymethyloxy-
carbonyl)methyl]-2-pyrrolidinone
(6) (3S,5S)-3-[[(1-acetoxyethyl)oxycarbonyl]methyl]-5-
[(4'-benzyloxycarbonylamidino-4-biphenylyl)oxymethyl]-
2-pyrrolidinone
(7) (3S,5S) 3-[(benzoyloxymethyloxycarbonyl)methyl]-5-
[~4'-benzyloxycarbonylamidino-4-biphenylyl)oxymethyl]-2-
pyrrolidinone
- ~7 - ~ ;
(8) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[(cyclohexyloxycarbonyloxy)-
methyloxycarbonyl]methyl]-2-pyrrolidinone
(9) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[(cyclopentyloxycarbonyloxy)-
methyloxycarbonyl]methyl]-2-pyrrolidinone
(10) ~3S,5S)-5-[(~'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-1-phenyl-3 [(pivaloyloxymethyloxy-
carbonyl)methyl~-2-pyrrolidinone
(11) (3S,5S)-1-benzyl-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-~(pivaloyloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone
(12) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4
biphenylyl)oxymethyl]-1-[2-(3,4-dimethoxyphenyl)ethyl]-
3-[(pivaloyloxymethyloxycarbonyl)methyl]-2-pyrrolidinone
(13) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-1-(2-methoxyethyl)-3-[(pivaloyloxy
methyloxycarbonyl)methyl]-2-pyrrolidinone
(14) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-l-[(morpholino-N-carbonyl)methyl]-
3-[(pivaloyloxy-methyloxycarbonyl)methyl]-2-
pyrrolidinone
(15) (3s~5s)-l-acetyl-5-[(4l-benzyloxycarbonylamidlno-4
biphenylyl)oxymethyl]-3-[[[1-(ethyloxycarbonyloxy)ethyl]
oxycarbonyl]methyl]-pyrrolidine
(16) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[[1-(ethyloxycarbonyloxy)ethyl]
oxycarbonyl]methyl]-1-methanesulphonyl-pyrrolidine
~ ~ S ~ J ~)
-- 4~3 --
(17) (3S,5S)-1-benzoyl-5-[(4'-benzyloxycarbonylamidino-
4-biphenylyl)oxymethyl]-3-~[[~-(ethyloxycarbonyloxy)-
ethyl]oxycarbonyl]methyl]-pyrrolidine
(18) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[[1-(pivaloyloxy)butyl]oxy-
carbonyl]methyl]-2-pyrrolidinone
(19) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[tl-(butyloxycarbonyloxy)-
ethyl]oxycarbonyl]methyl]-2-pyrrolidinone
(20) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[(cyclohexylcarbonyloxymethyl)-
oxycarbonyl]methyl]-2-pyrrolidinone
(21) (3R,S;4R,S)-4-[(4'-ben~yloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-methyl-3-[(pivaloyloxymethyloxy-
carbonyl)methyl]-2-pyrrolidinone
(22) (3R,S;4~,S)-4-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)carbonylaminomethyl]-3-[[[1-
(ethyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-2-
pyrrolidinone
(23) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-3-fluoro-4-
biphenylyl)oxymethyl]-3-[(pivaloyloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone
(24) ~3S,5S)-5-[(7-benæyloxycarbonylamidino-9,10-
dihydro-2-phenanthrenyl)oxymethyl]-3-[[[1-
(cyclohexyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-
2-pyrrolidinone
(25) (3S,5S)-5-[(7-benzyloxycarbonylamidino-2-
fluorenyl)oxymethyl]-3-[(pivaloyloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone
_ "9 _
(26) (3S,5S~-5-[(~'-methoxycarbonylamidino-4-
biphenylyl)oxym~thyl]-3-[(pivaloyloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone x 0.5 water
Rf value: 0.35 ~silica gel; methylene chloride/acetone =
6S:35)
Calculated: C 61.30 H 6.25 N 7.66
Found: 61.40 6.20 7.38
Mass spectrum: (M+H)~ = 540
(27) (3S,5S)-3~[[[l-~ethyloxycarbonyloxy)ethyl]oxy-
carbonyl]methyl]-5-[(4'-methoxycarbonylamidino-4-
biphenylyl)oxymethyl]-2-pyrrolidinone
(28) (3S,5S)-3-[[[l-~cyclohexyloxycarbonyloxy)ethyl]-
oxycarbonyl]methyl]-5-[(4'-methoxycarbonylamidino-4-
biphenylyl)oxymethyl]-2-pyrrolidinone
(29) (3S,5S)-5-[(4'-ethoxycarbonylamidino-4-
biphenylyl)oxymethyl]-3- L (pivaloyloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone
(30) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[[l-(propionyloxy)ethyl]oxy-
carbonyl]methyl]-2-pyrrolidinone
(31) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[[l-(cycloheptyloxy-
carbonyloxy)ethyl]oxycarbonyl]methyl~-2-pyrrolidinone
(32) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[[1-(isopropyloxycarbonyloxy)-
ethyl]oxycarbonyl]methyl]-2-pyrrolidinone
(33) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-~[[l-(isobutyloxycarbonyloxy)-
ethyl]oxycarbonyl]methyl]-2-pyrrolidinone
- 5() -
(34) (3S ! 5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[[1-(tert.butyloxycarbonyloxy)-
ethyl]oxycarbonyl]methyl]-2-pyrrolidinone
(35) (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[[1-(propyloxycarbonyloxy)-
ethyl]oxycarbonyl]methyl]-2-pyrrolidinone
Example 3
(3S,5S)-5-[(4'-Amidino-4-biphenylyl)oxymethyl]-3-[[[1-
(cyclohexyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-2-
pyrrolidinone x 1.1 HCl x 0.5 water
1.1 g of (3S,5S)-5-[(4'-benzyloxycarbonylamidino-4-
biphenylyl)oxymethyl]-3-[[[1-(cyclohexyloxycarbonyloxy)-
ethyl]oxycarbonyl]methyl]-2-pyrrolidinone, dissolved in
10 ml of dimethylformamide, are mi~ed with 3.26 ml of
0.5N hydrochloric acid and hydrogenated with 0.2 g of
palladium on charcoal (10% palladium) at ambient
temperature under a hydrogen pressure of 3.4 bar. After
2~ hours the mixture is suction filtered, the filtrate
is combined with saturated saline solution and extracted
three times with tetrahydrofuran. The combined organic
phases are washed with saturated saline solution,
filtered and evaporated down. The residue is stirred
with diethylether and the supernatant solution is
decanted off. The residue is dried in the desiccator
over concentrated sulphuric acid and potassium
hydroxide. Then it is triturated with diethylether,
suction filtered, washed with diethylether and dried.
Yield: 700 mg (75% of theory),
Rf value: 0.16 (Reversed Phase silica gel (RP8);
methanol/5~ aqueous saline solution =
6:4)
Calculated: C 59.37 H 6.37 N 7.16 Cl 6.65
Found: 58.94 6.45 7.14 6.77
~ J~3
Mass sp~ctrum: (M~ = 538
The followin~ are obtained analogously:
(1) (3S,5S)-5-L(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[l-(ethyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-2-
pyrrolidinone x 1.05 HCl x 0.5 water
Rf value: 0.34 (Reversed Phase silica gel (RP8);
methanol/5~ aqueous saline solution =
6:4)
Calculated: C 56.57 H 5.90 N 7.92 Cl 7.01
Found: 56.51 5.93 7.88 7.10
Mass spectrum: (M+H) = 484
(2) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(pivaloyloxymethyloxycarbonyl)methyl]-2-pyrrolidinone x
1.1 HCl x 0.5 water
Rf value: 0.30 (Reversed Phase silica gel (RP8);
methanol/5% aqueous saline solution =
6:4)
Calculated: C 58.85 H 6.29 ~ 7.92 Cl 7.35
Found: 58.69 6.21 7.75 7.40
Mass spectrum: (M+H)+ = 482
(3) (3S,5S)-3-[(acetoxymethyloxycarbonyl)methyl]-5-[(4'~
amidino-4-biphenylyl)oxymethyl]-2-pyrrolidinone-
hydrochloride
(4) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(butyryloxymethyloxycarbonyl)methyl]-2-pyrrolidinone-
hydrochloride
(5) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(isobutyryloxymethyloxycarbonyl)methyl]-2-
pyrrolidinone-hydrochloride
(6) (3S,5S)-3-[[(1-acetoxyethyl)oxycarbonyl]methyl]-5-
- 52 -
[(4'-amidino-4-biphenylyl)oxymethyl]-2-pyrrolidinone-
hydrochlQrlde
(7) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(benzoyloxymethyloxycarbonyl)methyl]-2-pyrrolidinone-
hydrochloride
(8) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(cyclohexyloxycarbonyloxy)methyloxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(~) (3S,5S)-5-[(4-amidino-4-biphenylyl)oxymethyl]-3-
[[(cyclopentyloxycarbonyloxy)methyloxycarbonyl]methyl]-
2-pyrrolidinone-hydrochloride
(10) (3S,5S)-5-[(4'-amidino-4-b.iphenylyl)oxymethyl]-1-
phenyl-3-[(pivaloyloxymethyloxycarbonyl)methyl]-2-
pyrrolidinone-hydrochloride
(11) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-1-
benzyl-3-[(pivaloyloxymethyloxycarbonyl)methyl]-2-
pyrrolidinone-hydrochloride
(12) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-1-
[2-(3,4-dimethoxyphenyl~ethyl]-3-[(pivaloyloxy-
methyloxycarbonyl)methyl]-2-pyrrolidinone-hydrochloride
(13) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-1-
(2-methoxyethyl)-3-[(pivaloyloxymethyloxycarbonyl)-
methyl]-2-pyrrolidinone-hydrochloride
(14) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-1-
[(morpholino-N-carbonyl)methyl]-3-[(pivaloyloxy-
methyloxycarbonyl)methyl]-2-pyrrolidinone-hydrochloride
(15) (3S,5S)-l-acetyl-5-[(4'-amidino-4-biphenylyl)-
oxymethyl]-3-[[[1-(ethyloxycarbonyloxy)ethyl]-
, ¢~
oxycarbonyl]methyI1-pyrrolidine-hydrochlori.de
(16) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[~[l-tethyloxycarbonyloxy)ethyl]vxycarbonyl]methyl]-l-
methanesulphonyl-pyrrolidine-hydrochloride
(17) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-1-
benzoyl-3-[[[1-(ethyloxyearbonyloxy)ethyl]oxycarbonyl]-
methyl]pyrrolidine-hydrochloride
(18) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[l-(pivaloyloxy)butyl]oxycarbonylmethyl]-2-
pyrrolidinone-hydrochloride
(19) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[1-(butyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(2Q) (3S,5S~-5-[(4' amidino-4-biphenylyl)oxymethyl]-3-
[[(cyclohexylcarbonyloxymethyl)oxyearbonyl]methyl]-2-
pyrrolidinone-hydrochloride
~21) (3R,S;4R,S)-4-[(4'~amidino-4-biphenylyl)oxymethyl]-
3-methyl-3-[(pivaloyloxymethyloxycarbonyl)methyl]-2-
pyrrolidinone-hydrochloride
(22) (3R,S;4R,S)-4-[(4'-amidino-4-biphenylyl)carbonyl-
aminomethyl]-3-[[[1-(ethyloxycarbonyloxy)ethyl]-
oxycarbonyl]methyl]-2-pyrrolidinone-hydrochloride
(23) (3S,5S)-5-[(4'-amidino-3-fluoro-4-biphenylyl)-
oxymethyl]-3-[(pivaloyloxymethyloxycarbonyl)methyll-2-
pyrrolidinone-hydrochloride
(24) (3S,5S)-5-[(7-amidino-9,10-dihydro-2-
phenanthrenyl)oxymethyl]-3-[[[l~(cyclohexyloxycarbonyl-
oxy)ethyl]oxycarbonyl]methyl]-2-pyrrolidinone-
e
~ 5~1 ~hydroch:Loride
(25) (3S,5S)-5-[(7-amidino-2-fluorenyl)oxymethyl]-3-
[(pivaloyloxymethyloxycarbonyl)methyl]-2-
pyrrolidinone-hydrochloride
(26) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[l-(propionyloxy)ethyl~oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(27) (3S,5S)-5-~(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[1-(cycloheptyloxycarbonyloxy)ethyl]oxycarbonyl]-
methyl]-2-pyrrolidinone-hydrochloride
(28) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[l-(isopropyloxycarbonyloxy)ethyl]oxycarbonyl]-
methyl]-2-pyrrolidinone-hydrochloride
(29) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[l-(isobutyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-
2-pyrrolidinone-hydrochloride
(30) (3S,5S)-5-~(4'-amidino-4-biphenylyl)oxymethyl]~3-
[[[l-(tert.butyloxycarbonyloxy)ethyl]oxycarbonyl]-
methyl]-2-pyrrolidinone-hydrochloride
(31) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[l-(propyloxycarbonyloxy)ethyl]oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
Example 4
(3S,5S)--5-[(4'-Amidino-4-biphenylyl)oxymethyl]-3-
[(cyclohexyloxycarbonyl)methyl]-2-pyrrolidinone x 1.05
HCl x 0.5 water
Hydrogen chloride gas is passed, with stirring, over a
Q~ ~
suspension of 1.5 g of (3S,5S)-5-[(4'-amidino-4-
biphenylyl)oxymethyl]-3-carboxymethyl-2-pyrrolidinone in
15 ml of cyclohexanol. The reaction mixture i5 then
stirred for 2 hcurs at 70C, during which time hydrogen
chloride gas is passed over it from time to time. The
reaction mixture is cooled, mixed with ether, the
precipitate is suction filtered and dried in the
desiccator over potassium hydroxide and conc. sulphuric
acid. The crude product is taken up in 400 ml of
methylene chloride, filtered and concentrated by
evaporation. The residue is stirred with
acetone/diethylether, suction filtered, washed with
diethylether and dried in the desiccator and in the
drying cupboard at 40C.
Yield: 1.7 g (85% of theory),
Rf value: 0.26 (Reversed Phase silica gel (RP8);
methanol/5~ aqueous saline solution =
6:4)
Calculated: C 62.85 H 6.70 N 8.46 Cl 7.49
Found: 62.88 6.76 8.45 7.52
Mass spectrum: (M+H)+ = 450
The following are obtained analogously:
(1) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(cyclohexylmethyloxycarbonyl)methyl]-2-pyrrolidinone x
1.08 HCl x 0.5 water
Rf value: 0.18 (Reversed Phase silica gel (RP8);
methanol/5% aqueous saline solution =
6:4)
Calculated: C 63.34 H 6.91 N 8.21 Cl 7.48
Found: 63.16 7.01 8.29 7.61
Mass spectrum: (M+H)+ = 464
(2) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(cyclopentyloxycarbonyl)methyl]-2-pyrrolidinone x 1.05
HCl x 0.5 water
f value: 0.27 (~ever~ed Phase silica gel (RP8);
methano]/5~ aqueous saline solution =
6:4)
Calculated: C 62.19 Il 6.48 N 8.70 Cl 7.71
Found: 62.05 6.70 8.82 7.79
Mass spectrum: (M+H)~ = 436
(3) (3S,5S)-5-[(4'-amidino-4-biphenylyl~oxymethyl]-3-
[(cycloheptyloxycarbonyl)methyl]-2-pyrrolidinone x 1.1
HCl x 1 water
Rf value: 0.16 (Reversed Phase silica gel (RP8);
methanol/5% aqueous saline solution =
6:4)
Calculated: C 62.16 H 6.97 N 8.05 Cl 7.48
Found: 62.33 7.15 7.96 7.63
(4) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(cyclooctyloxycarbonyl)methyl]-2-pyrrolidinone-
hydrochloride
(5) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[t(N-methylpiperidin-4-yl)oxycarbonyl]methyl]-2-
pyrrolidinone-dihydrochloride
(6) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[(tetrahydrofuran-2-yl)methyl]oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(7) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[2-(cyclohexyl)ethyl]oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
~8) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(2-cyclopentylmethyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(9) (3S,5S)-5-[(4'-amidino-4-biphenylyl~oxymethyl]-3-
- 57 -
[[(cycloheptylmethyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(10) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(N-methylpiperidin-3-yl)oxycarbonyl]methyl]-~--
pyrrolidinone-dihydrochloride
tll) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(N-ethylpiperidin-4-yl)oxycarbonyl]methyl]-2-
pyrrolidinone-dihydrochloride
(12) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[(N-methylpyrrolidin-2-yl)methyl]oxycarbonyl]methyl]-
2-pyrrolidinone-dihydrochloride
(13) ~3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(tetrahydrofuran-3-yl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(14) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(2-methylcyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(15) (3S,5S)-5-[(4'-Amidino-4-biphenylyl)oxymethyl]-3-
[[(3-methylcyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(16) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(4-methylcyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(17) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[~3,5-dimethylcyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(18) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-
3-[[(3,3,5-trimethylcyclohexyl)oxycarbonyl]methyl]-2-
- 58 -
pyrrolidinone-hydrochloride
(19) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-
3-[[(3,3,5,5-tetramethylcyclohexyl)oxycarbonyl]methyl]-
2-pyrrolidinone-hydrochloride
(20) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-
3-[[(4-ethylcyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(21) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-
3-[[(4-isopropylcyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(22) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-
3-[[(4-tert.butylcyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(23) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(methyloxycarbonyl)methyl]-2-pyrrolidinone-
hydrochloride
(24) (3S,5S)--5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(4-methoxycyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(25) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(4-ethoxycyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-hydrochloride
(26) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(4-dimethylaminocyclohexyl)oxycarbonyl]methyl]-2-
pyrrolidinone-dihydrochloride
(27) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(4-trifluoromethylcyclohexyl)oxycarbonyl]methyl]-
2-pyrrolidinone-hydrochloride
~ ~ v ~
- 59 -
(28) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[(3-methylnorbornan-2-yl)methyl]oxycarbonyl]methyl]-2-
pyrrolidinone-hydroehloride
(29) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(2-norbornyl)oxycarbonyl~methyl]-2-pyrrolidinone-
hydrochloride
(30) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[(myrtanyloxyearbonyl)methyl]-2-pyrrolidinone-
hydrochloride
(31) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[[2-(6,6-dimethyl-bicyelo[3.1.1]hept-2-
yl)ethyl]oxycarbonyl]methyl]-2-pyrrolidinone-
hydrochloride
(32) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-~-
[(einnamyloxyearbonyl)methyl]-2-pyrrolidinone-
hydroehloride
(33) (3S,5S)-5-[(4'-amidino-4-biphenylyl)oxymethyl]-3-
[[(2-indanyl)oxycarbonyl]methyl]-2-pyrrolidinone-
hydrochloride
Example 5
(3S,5S)-3-[(Cyclohexyloxycarbonyl)methyl]-5-[(4'-
methoxycarbonylamidino-4-biphenylyl)oxymethyl]-2-
pyrrolidinone
To a mixture of 1.1 g of (3S,5S)-5-[(4'~amidino-4-
biphenylyl)oxymethyl]-3-[(cyclohexyloxycarbonyl)methyl]-
2-pyrrolidinone x 1.05 HCl x 0.5 water in 30 ml of
tetrahydrofuran and 5 ml of water are added 0.2 ml of
methylchloroformate and then 9.6 ml of 0.5N sodium
hydroxide solution are added dropwise with stirring.
U ~ 3
- 6~ -
The reaction mixture is evaporated down, mixed with ice
water and the solid matter is suction filtered and
dried. After chromatography over a silica gel column
with ethyl acetate, a solid substance is obtained which
is boiled with 20 ml of ethyl acetate. After cooling,
the mixture is suct:ion filtered, washed with
diethylether and dried.
Yield: 570 mg (50% of theory),
Rf value: 0.27 (silica gel; ethyl acetate)
Calculated: C 66.26 H 6.55 N 8.28
Found: 65.96 6.54 8.37
Mass spectrum: (M+H~+ = 508
The following are obtained analogously:
(1) (3S,5S)~3-[(cyclohexylmethyloxycarbonyl)methyl]-5-
[(4'-ethoxycarbonylamidino-4-biphenylyl)oxymethyl]-2-
pyrrolidinone
(2) (3S,5S)-3-[(cyclopentyloxycarbonyl)methyl]-5-[(4'-
methoxycarbonylamidino-4-biphenylyl)oxymethyl]-2-
pyrrolidinone
(3) (3S,5S)-3-[(cycloheptyloxycarbonyl)methyl]-5-[(4'-
methoxycarbonylamidino-4-biphenylyl)oxymethyl]-2-
pyrrolidinone
(4) (3S,5S)-3-[(cyclooctyloxycarbonyl)methyll-5-[(4'-
methoxycarbonylamidino-4-biphenylyl)oxymethyl]-2-
pyrrolidinone
~ J ~v~
- Gl -
Example_-,
(3S,5S)-5-[[4'-(O,O'-Diethylphosphono)amidino-4-biphenyl
yl]oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone
. _
To a mixture of 1.1 y of (3S,5S)-5-[(4'-amidino-4-
biphenylyl)oxymethyl]-3-[(methoxycarbonyl)methyl]-2-
pyrrolidinone-toluenesulphonate in 20 ml of
tetrahydrofuran and 2 ml of water are added 380 mg of
diethylphosphate chloride and then 8.4 ml of 0.5N sodium
hydroxide solution are added dropwise, with stirring.
Some more diethylphosphate chloride and sodium hydroxide
solution are added and the mixture is stirred again.
The organic solvent is removed by rotary evaporation,
the aqueous phase is decanted off and the oily residue
is purified by chromatography over a silica gel column
with methylene chloride/methanol (95:5).
Yield: 0.47 g (45% of theory),
Rf value: 0.13 (Reversed Phase silica gel (RP8);
methanol/5% aqueous saline solution =
6:4)
Calculated: C 58.02 H 6.23 N 8.12
~ound: 57.88 6.42 8.30
Mass spectrum: M+ = 517
_ample 7
Dry ampoule containing 2.5 mg of active substance per
1 ml
_
Com~osition:
Active substance 2.5 mg
Mannitol 50.0 mg
Water for injections ad 1.0 ml
3 ~
62 -
_r~aratLon:
The active substance and mannitol are dissolved in
water. After transferring the solution to the ampoule,
it is freeze-dried.
At the point of use, the solution is made up with water
for înjections.
Exam~le 8
Tablet containing 50 mg of active substance
Com~osition:
(1) Active substance 50.0 mg
(2) Lactose 98.0 mg
(3) Corn starch 50.0 mg
(4) Polyvinylpyrrolidone15.0 mg
(5) Magnesium stearate 2.0 m~
215.0 mg
Preparation:
(1), (2) and (3) are mixed together and granulated with
an aqueous solution of (4). (5) is added to the dried
granules. From this mixture, compressed tablets are
produced, biplanar, facetted on both sides and notched
on one side. Diameter of tablets: 9 mm.
Example 9
Tablet containing 350 mg of active substance
_
Composition:
(1) Active substance 350.0 mg
- 63 -
(~) Lactose 136.0 mg
(3) Corn starch 80.0 mg
(4) Polyvinylpyrrolidone 30.0 mg
(5~ Magnesium stearate 4.0 mg
600.0 mg
Preparation:
(l), (2) and (3) are mixed together and granulated with
an aqueous solution of (4). (5) is added to the dried
granules. From this mixture, compressed tablets are
produced, biplanar, facetted on both sides and notched
on one side. Diameter of tablets: 12 mm.
Example 10
Capsules containing 50 mg of active substance
.. . . _
Composition:
(l) Active substance 50.0 mg
(2) Dried corn starch 58.0 mg
(3) Powdered lactose 50.0 mg
(4) Magnesium stearate 2.0 mq
160.0 mg
Preparation:
(l) is triturated with (3). This triturate is added to
the mixture of (2) and (4), wlth thorough mixing.
This powdered mixture is packed into size 3 hard gelatin
oblong capsules in a capsule filling machine.
~ i ~ t~ tJ ~3 ~ 9
Example_ll
Capsules containing 350 mg of active substance
.. . ..
Composition:
(1) Active substance 350.0 mg
(2) Dried corn starch 46.0 mg
~3) Powdered lactose 30.0 mg
~4) Magnesium stearate 4.0 mq
430.0 mg
Preparation:
(1) is triturated with (3). This triturate is added to
the mixture of (2) and (4), with thorough mixing.
This powdered mixture is packed into size O hard gelatin
oblong capsules in a capsule filling machine.
